Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (OTC:BSEM) reported first quarter 2026 results and strategic updates.
Net revenue was $6.1M, mainly from Neox and Clarix, with hospitals contributing 87% ($5.4M) and physician offices $0.8M. Gross profit was $3.8M with 61% margin. Operating expenses were $12.6M; GAAP net loss was $8.8M ($0.52/share) and adjusted EBITDA was ($5.7M). Cash was $13.7M on March 31, 2026.
The company advanced integration of acquired BioTissue assets, expanded its direct sales force to 35, retired approximately $5.3M of GMA debt, completed 2024–2025 audits, and is progressing toward a planned Nasdaq uplisting. BioStem guides 2026 revenue to $25–$29M.
BioStem Technologies (OTC:BSEM) announced that company management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA.
The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET, with live and archived webcasts available on the company’s investor relations website.
BioStem Technologies (OTC: BSEM) will release first quarter 2026 financial results on Thursday, May 14, 2026 and will host a conference call and webcast at 4:30 PM ET.
The webcast will include an overview of the quarter from management. Registration and live access details are provided via a webcast link and conference call numbers.
BioStem Technologies (OTC: BSEM) appointed Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026.
Gorrell brings ~20 years of health‑law and compliance experience, will oversee legal, compliance, enterprise governance and integration of Medical Affairs, and will support BioStem’s growth and stated efforts toward a Nasdaq uplisting.
BioStem Technologies (OTC: BSEM) will present at the Symposium on Advanced Wound Care Spring 2026 in Charlotte, April 8–12. The company will showcase its newly introduced Neox product line, host an Innovation Theater lunch on April 9 (12:15–1:45pm ET, Room 207C) and present poster LR-020 in Exhibit Hall 1C.
Sessions cover randomized controlled trial results on diabetic foot ulcers, real-world evidence, product handling, and clinical adoption guidance for placental and umbilical cord tissue therapies.
BioStem Technologies (OTC: BSEM) announced management will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 8:45 am ET.
Live and archived webcasts will be available on the company’s investors page at ir.biostemtechnologies.com for interested parties and investors.
BioStem Technologies (OTC: BSEM) announced it filed audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025 on March 30, 2026. The company said publication of audited statements, plus new finance leadership, advances its goal of a Nasdaq uplisting.
BioStem named a new CFO, auditor and audit committee chair and said these steps strengthen financial reporting processes and support corporate initiatives including a potential Nasdaq listing to increase visibility and liquidity.
BioStem Technologies (OTC: BSEM) reported Q4 2025 net revenue of $10.1 million and full-year 2025 revenue of $47.5 million, with Q4 gross margin of 97% and full-year gross margin of 94%. GAAP net loss was ($11.3 million) in Q4 and ($6.6 million) for 2025.
The company completed the BioTissue surgical and wound asset acquisition on Jan 21, 2026, integrated ~20 direct reps plus 30+ agents, and reported cash equivalents of $29.5 million at Dec 31, 2025 (post-close cash ~$16 million).
BioStem Technologies (OTC: BSEM) appointed Jodi Ungrodt to its Board of Directors and named her Audit Committee Chair, effective March 18, 2026. Ungrodt brings 29 years of life‑sciences accounting leadership and is qualified as a financial expert under SEC, NYSE, and NASDAQ rules.
Her experience includes advising 30+ IPOs, serving more than 70 life‑sciences clients at Ernst & Young, and prior audit committee leadership; she will oversee financial reporting, internal controls and risk management as BioStem pursues public‑market visibility in 2026.
BioStem Technologies (OTC: BSEM) will release its fourth quarter and full year 2025 financial results on March 24, 2026 and host a conference call and webcast at 4:30 PM ET.
Presenters include CEO Jason Matuszewski and CFO Brandon Poe. Registration and webcast access are available via the company's provided links and phone numbers.